PTC Therapeutics (PTCT) Misses Q1 EPS by 24c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. RTX
8. SMCI
9. GOOGL
10. S

Go back to PTC Therapeutics (PTCT) Misses Q1 EPS by 24c

PTC Therapeutics Provides a Corporate Update and Reports First Quarter Financial Results

May 3, 2022 4:01 PM EDT

- $149 million total revenue representing impressive 26% year-over-year growth

- Initiation of PIVOT-HD Phase 2 trial of PTC518 in Huntington's disease

- CHMP opinion on AADC gene therapy expected in May; ready to execute on potential launch

SOUTH PLAINFIELD, N.J., May 3, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and financial results for the first quarter ending March 31, 2022.

"We are continuing to build a robust... More